Neurogen is seeking partnerships in neuroscience, pain and inflammatory diseases
Neurogen Corp. business development
Neurogen is a small molecule drug discovery and development company targeting new drug candidates to improve the lives of patients suffering from pain, insomnia, inflammation, depression and obesity.
They are concentrating their efforts on key therapeutic areas (neuroscience, pain and inflammation) within which clinical indications may be developed for a variety of disorders, balancing risk against potential value.
They believe that their ability to produce multiple generations of candidates in multiple programs using AIDD (TM) distinguishes Neurogen as a leading drug discovery and development company.
Neurogen's partnering strategy seeks to retain ownership and control of programs as far downstream as possible, balancing risk for the Company while maximizing return for shareholders. They are building capabilities internally to take programs further in clinical development. These capabilities enable them to pursue a flexible business model, using partnered programs when they feel it will be competively and economically advantageous to do so.
When they partner their programs they seek to collaborate with pharmaceutical leaders with demonstrated strenght and resources which complement their own.